TheEdgeResearch
Home / Stocks / PGEN

Precigen, Inc. (PGEN)

NASDAQ Healthcare Biotechnology
$4.34 ▼ -3.77%
Market Cap
$1.30B
Sector
Healthcare
Industry
Biotechnology
Beta
1.07
52-Wk Range
1.28-5.47
CEO
Helen Sabzevari
Country
US
Currency
USD

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral tr…

Open full interactive analysis & DCF →